This paper is in the following e-collection/theme issue:

Methods and Feasibility Studies (383) Dementia and Cognitive Decline (497) Diagnostic Tools in Mental Health (246) Methods and New Tools in Mental Health Research (461)

Published on in Vol 11, No 8 (2022): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35442, first published .
Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study

Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study

Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study

Authors of this article:

Jelena Curcic1 Author Orcid Image ;   Vanessa Vallejo1 Author Orcid Image ;   Jennifer Sorinas1 Author Orcid Image ;   Oleksandr Sverdlov2 Author Orcid Image ;   Jens Praestgaard3 Author Orcid Image ;   Mateusz Piksa1 Author Orcid Image ;   Mark Deurinck1 Author Orcid Image ;   Gul Erdemli3 Author Orcid Image ;   Maximilian Bügler4 Author Orcid Image ;   Ioannis Tarnanas4, 5 Author Orcid Image ;   Nick Taptiklis6 Author Orcid Image ;   Francesca Cormack6 Author Orcid Image ;   Rebekka Anker7 Author Orcid Image ;   Fabien Massé7 Author Orcid Image ;   William Souillard-Mandar8, 9 Author Orcid Image ;   Nathan Intrator10 Author Orcid Image ;   Lior Molcho10 Author Orcid Image ;   Erica Madero11 Author Orcid Image ;   Nicholas Bott12 Author Orcid Image ;   Mieko Chambers13 Author Orcid Image ;   Josef Tamory13 Author Orcid Image ;   Matias Shulz14 Author Orcid Image ;   Gerardo Fernandez14 Author Orcid Image ;   William Simpson15 Author Orcid Image ;   Jessica Robin15 Author Orcid Image ;   Jón G Snædal16 Author Orcid Image ;   Jang-Ho Cha3 Author Orcid Image ;   Kristin Hannesdottir3 Author Orcid Image
Article Authors Cited by (2) Tweetations (10) Metrics

Jelena Curcic   1 , PhD ;   Vanessa Vallejo   1 , PhD ;   Jennifer Sorinas   1 , PhD ;   Oleksandr Sverdlov   2 , PhD ;   Jens Praestgaard   3 , PhD ;   Mateusz Piksa   1 , MSc ;   Mark Deurinck   1 , DVM, Dr med vet ;   Gul Erdemli   3 , MD, PhD ;   Maximilian Bügler   4 , PhD ;   Ioannis Tarnanas   4, 5 , PhD ;   Nick Taptiklis   6 , PhD ;   Francesca Cormack   6 , PhD ;   Rebekka Anker   7 , MSc ;   Fabien Massé   7 , PhD ;   William Souillard-Mandar   8, 9 , PhD ;   Nathan Intrator   10 , PhD ;   Lior Molcho   10 , PhD ;   Erica Madero   11 , PhD ;   Nicholas Bott   12 , PhD ;   Mieko Chambers   13 , PhD ;   Josef Tamory   13 , BS, COA, OSC ;   Matias Shulz   14 , PhD ;   Gerardo Fernandez   14 , PhD ;   William Simpson   15 , PhD ;   Jessica Robin   15 , PhD ;   Jón G Snædal   16 , MD ;   Jang-Ho Cha   3 , MD, PhD ;   Kristin Hannesdottir   3 , PhD

1 Novartis Institutes for Biomedical Research, Basel, Switzerland

2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States

3 Novartis Institutes for Biomedical Research, Cambridge, MA, United States

4 Altoida Inc, Washington, DC, United States

5 Global Brain Health Institute, Trinity College, Dublin, Ireland

6 Cambridge Cognition Ltd, Cambridge, United Kingdom

7 MindMaze SA, Lausanne, Switzerland

8 Linus Health, Boston, MA, United States

9 Massachusetts Institute of Technology, Cambridge, MA, United States

10 Neurosteer Inc, New York, NY, United States

11 Neurotrack Technologies Inc, Redwood City, CA, United States

12 Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States

13 Neurovision Imaging Inc, Sacramento, CA, United States

14 ViewMind Inc, New York, NY, United States

15 Winterlight Labs, Toronto, ON, Canada

16 Memory Clinic, Landspitali, Reykjavik, Iceland

Corresponding Author: